Penella J Woll, Piers Gaunt, Charlotte Gaskell, Robin Young, Charlotte Benson, Ian R Judson, Beatrice M Seddon, Maria Marples, Nasim Ali, Sandra J Strauss, Alexander Lee, Ana Hughes, Baljit Kaur, David Hughes, Lucinda Billingham
BACKGROUND: Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. METHODS: Axi-STS was a pathologically-stratified, non-randomised, open-label, multi-centre, phase II trial of continuous axitinib treatment in patients ≥16 years, performance status ≤2, with pathologically-confirmed advanced/metastatic soft tissue sarcoma (STS). Patients were recruited within four tumour strata, each analysed separately: angiosarcoma, leiomyosarcoma, synovial sarcoma, or other eligible STSs...
October 2023: British Journal of Cancer